Please use this identifier to cite or link to this item: https://doi.org/10.1002/emmm.201202183
Title: Oncogenic roles of PRL-3 in FLT3-ITD induced acute myeloid leukaemia
Authors: Park, J.E.
Yuen, H.F.
Zhou, J.B. 
Al-aidaroos, A.Q.O.
Guo, K.
Valk, P.J.
Zhang, S.D.
Chng, W.J.
Hong, C.W.
Mills, K.
Zeng, Q. 
Keywords: Acute myeloid leukaemia
Antibody therapy
FLT3-ITD mutation
PRL-3
Prognostic marker
Issue Date: Sep-2013
Citation: Park, J.E., Yuen, H.F., Zhou, J.B., Al-aidaroos, A.Q.O., Guo, K., Valk, P.J., Zhang, S.D., Chng, W.J., Hong, C.W., Mills, K., Zeng, Q. (2013-09). Oncogenic roles of PRL-3 in FLT3-ITD induced acute myeloid leukaemia. EMBO Molecular Medicine 5 (9) : 1351-1366. ScholarBank@NUS Repository. https://doi.org/10.1002/emmm.201202183
Abstract: FLT3-ITD mutations are prevalent mutations in acute myeloid leukaemia (AML). PRL-3, a metastasis-associated phosphatase, is a downstream target of FLT3-ITD. This study investigates the regulation and function of PRL-3 in leukaemia cell lines and AML patients associated with FLT3-ITD mutations. PRL-3 expression is upregulated by the FLT3-STAT5 signalling pathway in leukaemia cells, leading an activation of AP-1 transcription factors via ERK and JNK pathways. PRL-3-depleted AML cells showed a significant decrease in cell growth. Clinically, high PRL-3 mRNA expression was associated with FLT3-ITD mutations in four independent AML datasets with 1158 patients. Multivariable Cox-regression analysis on our Cohort 1 with 221 patients identified PRL-3 as a novel prognostic marker independent of other clinical parameters. Kaplan-Meier analysis showed high PRL-3 mRNA expression was significantly associated with poorer survival among 491 patients with normal karyotype. Targeting PRL-3 reversed the oncogenic effects in FLT3-ITD AML models in vitro and in vivo. Herein, we suggest that PRL-3 could serve as a prognostic marker to predict poorer survival and as a promising novel therapeutic target for AML patients. © 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.
Source Title: EMBO Molecular Medicine
URI: http://scholarbank.nus.edu.sg/handle/10635/117106
ISSN: 17574676
DOI: 10.1002/emmm.201202183
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

26
checked on Oct 17, 2018

WEB OF SCIENCETM
Citations

22
checked on Oct 17, 2018

Page view(s)

64
checked on Sep 21, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.